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Abstract
Background: People with ischemic heart disease have increased drastically, and their health-related quality of life
(HRQOL) has been increasingly important. The Coronary Revascularization Outcome Questionnaire (CROQ) is a widely
used tool to assess the quality of life in patients with coronary artery disease. The purpose of this study was
to rigorously examine the psychometric properties of the CROQ in patients who had undergone percutaneous
coronary intervention (PCI).
Methods: The CROQ was translated into Korean. A total of 209 patients before PCI and 169 patients after PCI were
recruited from a university hospital in Korea and completed questionnaires. In terms of statistical analyses, internal
consistency, concurrent validity with using the Short Form 12 (SF-12) and Seattle Angina Questionnaire-Korean version
(SAQ-K), and construct validity using exploratory factor analysis were assessed. Effective size statistics were calculated.
Results: The internal consistency coefficients for all subscales of the CROQ were above 0.70, except the domain of
adverse effects. The concurrent validity was mostly supported by the pattern of association among CROQ-K, SAQ-K,
and SF-12. The results of EFA showed the core items of the CROQ had 7 factors. Large effect sizes were observed for
the symptoms and the psychosocial functioning scales.
Conclusions: The Korean version of the CROQ is a valid and reliable scale for assessing HRQOL in patients with
coronary artery disease.
Keywords: Coronary revascularization outcome questionnaire, Percutaneous coronary intervention, Quality of life,
Reliability, Validity
Background
Ischemic heart disease (IHD) has been the leading cause
of death worldwide [1]. In Korea, heart disease is the
second major cause of death and has increased drastic-
ally due to the rapidly aging population and changes in
diet [2]. The cause of death of 71,174 of the 267,692
people who died in 2014 was cardiovascular disease,
including a considerable number of people who died
due to ischemic heart disease [2]. With the high mor-
tality associated with IHD, medical costs are
significantly higher for this condition compared to
other chronic diseases [3].
The development of new treatment methods and pre-
vention programs has been studied to reduce the mor-
tality and medical costs associated with IHD [4, 5].
Coronary revascularization, such as percutaneous coron-
ary intervention (PCI) and coronary artery bypass graft
surgery (CABG), is the most common procedure used to
treat IHD [4, 6]. Many studies have evaluated the ef-
fectiveness of coronary revascularization by referring
to the mortality rate or the results of clinical labora-
tory tests [4, 7]. However, mortality rates and labora-
tory findings do not fully reflect patient well-being
[8]. Quality of life should also be considered to deter-
mine the optimum treatment.
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The quality of life of patients with IHD rapidly de-
clines due to uncertainty about the prognosis of the dis-
ease and the burden of medical expenses [9, 10]. In
addition, there is a high risk of re-hospitalization due to
the relapse of acute coronary syndrome or complications
of the procedure [9, 11]. Therefore, disease-specific
health-related quality of life (HRQOL) should be
assessed to understand changes in quality of life in IHD
patients after revascularization.
Some generic measures, such as the SF-36 and the
Nottingham Health Profile (NHD), have been used to
evaluate quality of life in patients after revascularization.
However, these instruments were not designed to detect
changes in outcomes related to cardiac events. In
addition, generic instruments have been shown to be less
responsive to changes after treatment than are disease-
specific instruments [12].
Several disease-specific HRQOL questionnaires, such
as the Seattle Angina Questionnaire (SAQ) and the An-
gina Pectoris Quality of Life Questionnaire (APQLQ),
can assess the HRQOL of patients with coronary artery
disease. The SAQ has been translated into the Korean
language [13] and is used to evaluate outcomes related
to coronary artery disease [14]. Unfortunately, the SAQ
does not include items related to the adverse effects of
CABG or PCI. Thus, it is difficult to measure changes
after CABG or PCI, such as adverse effects.
The Coronary Revascularization Outcome Question-
naire (CROQ) was developed to assess not only the
HRQOL of patients with coronary artery disease, but
also the adverse effects of CABG or percutaneous trans-
luminal coronary angiography (PTCA) [15]. The validity
and reliability of the CROQ- CABG and PTCA have
been well established [15], and this inventory is just as
responsive as the SAQ and even more responsive to
change than the generic questionnaire [12]. It has also
been translated into Japanese and Persian languages
[16, 17], but a Korean version is not available. In
Korea, PCI is more commonly used than CABG to treat
IHD [18]. In this light, the aim of this study was to (1)
translate the CORQ-PTCA into Korean and (2) assess the




The CRQO-PTCA has two versions: the CROQ-
PTCA Pre-revascularization and the CROQ-PTCA
Post-revascularization. Both versions contain 32 core
evaluation items: symptoms (7 items), physical functioning
(8 items), cognitive functioning (3 items), and psychosocial
functioning (14 items), as well as one descriptive item that
is not included in the scale scores [15]. The CROQ has
additional post-revascularization items about satisfaction
(6 items) and adverse effects (6 items) and two descriptive
items that are not included in the scale scores. Each item
is rated using three six-point Likert scales. The items in
each scale are summed and then converted to a 0–100
scale, with 100 representing the best outcome.
Translation
The CROQ-PTCA was translated using standardized
forward-backward procedures [19]. First, the original
version of the CROQ-PTCA was obtained from the ori-
ginal author, and permission was granted for its use in
this study. Two nursing faculty members who were na-
tive Korean speakers and proficient in English translated
it into Korean. The translated version was evaluated for
clarity, word choice, and agreement with the original
version by an expert panel, including a cardiologist, a
preventive medicine physician, and two nursing faculty
members. The expert panel made the following changes:
(1) the terms “half a mile” and “100 yards” were changed
to “around 1 km” and “around 100 m” because Korea
uses the metric system. (2) The word “groin” was chan-
ged to “puncture site” because both the radial and fem-
oral sites are used for catheter insertion in the PCI
procedure in Korea. After the expert’s evaluation, the
tool was back-translated into English by a bilingual indi-
vidual. The expert panel then re-evaluated the back-
translated version of the CROQ-PTCA to assess its
agreement with the original version. After a professional
Korean editor proofread the final version, a pilot study
with 10 patients was conducted to evaluate whether the
Korean version of the CROQ-PTCA was clear and easy
to understand. This investigation led to some minor
modifications of the Korean medical terms.
Patients
Participants were recruited from cardiologic clinics in a
university hospital in J City, Korea. The inclusion criteria
were: (1) age 18 years or older; (2) diagnosed with IHD by
a cardiologist; (4) ability to read and write Korean; and (5)
intact cognitive function. The exclusion criterion was (1)
previous experiences with PCI or CABG. Eligibility to par-
ticipate was confirmed by the cardiologist who was one of
the co-investigators in this study. The eligible patients
were sorted into two groups on the basis of treatment
stage: a pre-PCI group who were recommended to
undergo elective PCI by a cardiologist and a post-PCI
group who had undergone PCI via the radial or femoral
artery three months prior. The three-month point was se-
lected because the majority of patients should have recov-
ered from the procedure by then, and only a few patients
would still be experiencing adverse effects.
Patients who met the inclusion criteria were invited to
participate in the study. After providing written informed
consent, the patients were asked to complete a series of
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questionnaires including the CROQ-PTCA, SAQ-K, and
SF-12-K with demographic characteristics. A total of 209
patients participated in the pre-PCI assessment. In
addition, 169 patients participated in the post-PCI assess-
ment. Twenty-eight patients completed both pre- and
post-PCI assessments. The data were collected between
January 2014 and December 2014, after receiving approval
from the institutional review board.
Measures
The Seattle Angina Questionnaire-Korean (SAQ-K) was
used to assess the concurrent validity of the CROQ-
PTCA (K). The SAQ-K consists of five domains: physical
limitations (nine items), angina stability (one item), an-
gina frequency (two items), treatment satisfaction (four
items), and quality of life (three items) [20]. Each item is
rated using 5–6-point Likert scales. Items in each scale
are summed and then converted to a 0–100 scale. A
score of 100 points represents the best outcome.
The SF-12 was also used to assess the concurrent val-
idity of the CROQ-PTCA (K). The SF-12 is an abbrevi-
ated version of the SF-36 and contains 12 items covering
eight domains (physical functioning, role-physical, bodily
pain, general health, vitality, social functioning, role-
emotional, and mental health), which produce two sum-
mary scores: the physical component summary (PCS)
and the mental component summary (MCS) scores. The
PCS and the MCS are standardized (mean = 50, SD = 10).
For each of the eight domains, the items are summed and
then converted to a 0–100 scale, with high scores indicat-
ing better outcomes.
Statistical analysis
Patient characteristics in the pre-PCI and post-PCI groups
were analyzed using descriptive statistics. Scores for each
domain of the CROQ-PTCA were evaluated by descriptive
analysis. Cronbach’s alpha was used to examine the internal
consistency, and the item-total correlation coefficients
were also computed. A Cronbach’s alpha ≥0.70 and item-
total correlation coefficients >0.2 were deemed statistically
acceptable [21]. Spearman’s rank correlation coefficients
between the scores of the CROQ-PTCA (K), SAQ-K, and
SF-12 (K) questionnaires were used to assess the concur-
rent validity. To evaluate the construct validity, an explora-
tory factor analysis (EFA) with varimax rotation was
performed. After an assessment of all eigenvalues greater
than 1, the number of domains was determined for the
core items, those associated with treatment satisfaction,
and items related to the adverse effects of PCI. Responsive-
ness was the ability of the scales to detect clinically import-
ant changes over time [22]. The Wilcoxon signed-rank test
was used to compare the results before and three months
after revascularization. Effect size statistics were calculated
as the mean change score between pre- and post-PCI
assessments divided by the standard deviation of scores at
the pre-PCI assessment [22].
Results
Patient characteristics
Table 1 shows the characteristics of participants. Most
participants were male (80.9% in the pre-PCI group,
76.9% in the post-PCI group) and lived with a spouse
(79.7% in the pre-PCI group, 74.0% in the post-PCI
group). The mean age was 60.8 (±10.56) years in the
pre-PCI group and 61.6 (±9.76) years in the post-PCI
group. The average number of years that patients had
been receiving treatment for ischemic heart disease was
3.51 in the pre-PCI group and 2.72 in the post-PCI group.
Scores and Reliability of the CROQ-PTCA (K)
The mean score of each domain and the reliability of the
CROQ-PTCA (K) are shown in Table 2. Cronbach’s al-
phas were computed for each domain based on the pre
and post-PCI data as indicators of internal consistency.
Cronbach’s alphas of the domains of symptoms, physical
functioning, cognitive functioning, and psychosocial
functioning in the core items in both the pre- and post-
PCI assessments as well as the domain of satisfaction in
the post-PCI assessment were ≥0.70. However, the do-
main of adverse effects had a Cronbach’s alpha of 0.47.
The means of the item-total correlations for the domains
of the CROQ-PTCA (K) ranged from 0.27–0.83.





n % n %
Sex Male 169 80.9 130 76.9
Female 40 19.1 39 23.1
Education ≤ Middle school 97 46.4 94 55.6
≥ High school 112 53.6 75 44.4
Income ≤100 64 30.9 58 34.3
(10,000 won) 101–300 94 45.4 82 48.5
≥301 49 23.7 29 17.2
Living arrangement With spouse 165 79.7 125 74.0
With someone 9 4.3 19 11.2
Alone 33 15.9 25 14.8
Employed No 70 33.5 65 38.5
Yes 139 66.5 104 61.5
Puncture site Radial artery 85 50.3
Femoral artery 84 49.7
Mean SD Mean SD
Age (years) 60.84 10.56 61.64 9.76
Duration of treatment (years) 3.51 4.79 2.72 2.90
PCI percutaneous coronary intervention
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Validity
The results of the exploratory factor analyses (EFA) of the
32 core items of the CROQ-PTCA (K) are shown in
Table 3. The analyses yielded seven factors that explained a
total of 79.4% of the variance in the pre-PCI test and 75.7%
in the post-PCI test. The KMO measure was 0.89 on the
pre-PCI test and 0.84 on the post-PCI test. Table 4 shows
the results of the EFA of items regarding satisfaction with
and adverse effects of the CROQ-PTCA (K)-Post. The do-
main of satisfaction was identified as having two factors,
which explained 80.3% of the variance. Regarding the items
related to these adverse effects, three factors were identi-
fied, which explained 76.9% of the variance.
Table 5 shows the correlation among the scores of the
CROQ-PTCA, SAQ, and SF-12. The CROQ symptom
had positive correlations with the PCS of the SF-12 in
the post-test and the angina frequency scale of the SAQ
in the pre- (r = 0.72) and post-PCI (r = 0.79) tests. The
CROQ physical functioning was positively correlated
with the PCS of the SF-12 (r = 0.62 and r = 0.43) and the
physical limitation scale of the SAQ (r = 0.86 and r = 0.87).
The CROQ cognitive functioning was positively correlated
with PCS (r = 0.50 and r = 0.37) and MCS (r = 0.34
and r = 0.43) of the SF-12 for both tests and with the qual-
ity of life scale of the SAQ in the pre-PCI test (r = 0.28).
The CROQ psychosocial functioning was positively
correlated with the PCS (r = 0.57 and r = 0.49) and
MCS (r = 0.31 and r = 0.52) of the SF-12 and the
quality of life scale of the SAQ (r = 0.45 and r = 0.45)
on both tests. The CROQ satisfaction was positively
correlated with the treatment satisfaction scale of the
SAQ (r = 0.59). The CROQ’s adverse effects were
positively correlated with the quality of life scale of
the SAQ (r = 0.22).
Responsiveness
Table 6 shows the results of the responsiveness analysis
for the CROQ based on the data of 28 patients who
completed both the pre- and post-PTCA questionnaires.
Large effect sizes were observed for the symptoms and
the psychosocial functioning scales.
Discussion
To our knowledge, this is the first report on the transla-
tion and validation of the CROQ-PTCA in the Korean
language. The results indicated that the Korean version
of the CROQ-PTCA was psychometrically sound and
appropriate for patients who undergo PCI procedures.
Regarding the translation procedure, the changes in
the terms used are consistent with the cultural and pro-
cedural characteristics in Korea. In this study, about half
of the patients received PCI via a radial artery. Evalu-
ation by the expert group and a pilot test confirmed the
content validity of the CROQ-PTCA (K).
According to the results of the analysis for the Cron-
bach’s alpha of each domain of the CROQ-PTCA (K), all
domains in the CROQ core items and the CROQ satisfac-
tion met the criteria value, which was a Cronbach’s alpha
of 0.7[21]. All items showed higher than 0.20 item-total
correlation coefficients in the CROQ core items [21], ex-
cept ‘frequency of use of nitroglycerin’ (0.16) in the CROQ
symptom in the pre-PCI assessment. The low item-total
correlation of ‘frequency of use of nitroglycerin’ might be
associated with the fact that only 18 patients had used
nitroglycerin (data not presented in tables) among 209
participants in the pre-test. However, the CROQ adverse
effects showed a low Cronbach’s alpha of 0.47 and a mean
of the item-total correlation coefficients of 0.27. Adverse
effects described in the original CROQ-PTCA were those
Table 2 Scores and Reliability of the CROQ-PTCA (K)
Mean (SD) Reliability (Cronbach’s α) Item-total correlation (Mean)
CROQ-PTCA Pre (N = 209)
Symptoms 74.88 (21.46) 0.80 0.16–0.77 (0.52)
Physical functioning 92.14 (15.95) 0.88 0.49–0.79 (0.68)
Cognitive functioning 96.91 (10.90) 0.91 0.75–0.87 (0.83)
Psychosocial functioning 93.22 (15.05) 0.96 0.65–0.88 (0.79)
CROQ-PTCA Post (N = 169)
Symptoms 94.76 (10.35) 0.78 0.37–0.71 (0.52)
Physical functioning 96.93 (9.69) 0.89 0.64–0.78 (0.70)
Cognitive functioning 96.21 (8.78) 0.89 0.84–0.89 (0.83)
Psychosocial functioning 85.52 (13.03) 0.92 0.42–0.77 (0.64)
Satisfaction 85.83 (14.66) 0.82 0.51–0.69 (0.61)
Adverse effects 98.35 (5.44) 0.47 0.08–0.45 (0.27)
Radial artery (n = 85) 98.62 (4.82) 0.33 0.03–0.51 (0.22)
Femoral artery (n = 84) 98.06 (6.01) 0.59 0.08–0.72 (0.42)
CROQ Coronary Revascularization Outcome Questionnaire, PTCA percutaneous transluminal coronary angioplasty
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that occur when a femoral artery was used, and the Cron-
bach’s alpha for this original version was 0.87 [15]. In a
Japanese study, the Cronbach’s alpha of the adverse effects
was 0.83, but no information about puncture site was
available [16]. However, many studies have reported that
the radial approach is a safe method compared to the
femoral approach due to a decreased risk of puncture
site complications [23–25]. In our study, the radial ar-
tery was used for half of the PCI procedures (Cron-
bach’s α = 0.33), and the mean score of adverse effects
was very high (98.35 of 100), indicating almost no
puncture site complications. Thus, the CROQ adverse
effects may not be adequate for patients receiving
PCI via the radial artery.
Seven factors were identified in the results of the EFA
of the CROQ-PTCA (K) core items, with 79.4% and
75.7% of the contribution ratios. All items had a loading
factor greater than 0.4 for the respective domain. The
original version has four domains, but has not been the
subject of EFA [15]. In the Japanese study, the four iden-
tified factors were almost the same as those found in the
original version, but the contribution ratio was only
54.3% [16]. In our study, CROQ psychosocial functioning
was separated into three factors of social activities, feelings
about oneself, and feelings about one’s relationships with
others. Physical functioning had two factors in the pre-test
but only one factor on the post-test. Some items of the
symptoms were identified as the same factor of physical
Table 5 Concurrent Validity of the CROQ-PTCA (K)






Scale (N = 208)
Angina Stability
Scale (N = 209)
Angina Frequency
Scale (N = 209)
Treatment Satisfaction
Scale (N = 209)
Quality of Life
Scale (N = 209)
CROQ-PTCA Pre
Symptoms 0.13 -0.21** 0.54** -0.17* 0.72** 0.44** 0.47**
Physical functioning 0.62** 0.23** 0.86** 0.38** 0.61** 0.18* 0.40**
Cognitive functioning 0.50** 0.34** 0.52** 0.22** 0.47** 0.09 0.28**





















Symptoms 0.27** 0.08 0.57** 0.02 0.79** 0.17* 0.39**
Physical functioning 0.43** 0.22** 0.87** 0.28** 0.55** 0.16* 0.27**
Cognitive functioning 0.37** 0.43** 0.10 0.02 <0.01 0.14 0.02
Psychosocial functioning 0.49** 0.52** 0.33** 0.05 0.18* 0.19* 0.45**
Satisfaction 0.36** 0.32** 0.15 0.01 0.07 0.591* 0.19*
Adverse effects 0.07 -0.06 0.14 -0.14 0.06 0.15 0.22**
*p < 0.05 **p < 0.01
CROQ Coronary Revascularization Outcome Questionnaire, PTCA percutaneous transluminal coronary angioplasty, SAQ Seattle Angina Questionnaire, PCS physical
component summary, MCS mental component summary
Table 4 Factor Analyses of CROQ-PTCA (K) Post Items
Satisfaction (n = 169) Adverse effects (n = 169)
Factor 1 Factor 1 Factor 1 Factor 1 Factor 1
Satisfaction with the results of the operation 0.89 0.26 Pain at the puncture site <0.01 0.84 0.24
Satisfaction with information about the operation 0.96 0.18 Tenderness around the puncture site 0.17 0.19 0.71
Satisfaction with information about recovering
from the operation
0.96 0.16 Numbness or tingling at the puncture site -0.02 0.89 -0.05
Heart condition compared to before the operation 0.17 0.80 Bruising around the puncture site 0.94 -0.02 0.02
Speed of recovery 0.13 0.81 Catheter-related problems at the puncture site -0.07 -0.03 0.85
Expectation of results 0.20 0.80 Concern over the appearance of bruises 0.94 0.01 0.07
Contribution rate 80.3% Contribution rate 76.9%
Kaiser-Meyer-Olkin 0.76 Kaiser-Meyer-Olkin 0.52
CROQ Coronary Revascularization Outcome Questionnaire, PTCA percutaneous transluminal coronary angioplasty
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functioning, such as palpitations on the pre-test and
shortness of breathing on the post-test. The CROQ cogni-
tive functioning contained one factor for both tests, while
three items were included for psychosocial functioning in
the pre-test. Although our findings were different from
those of a previous study [16], the factors of the CROQ-
PTCA (K) were reasonably identified.
In the results of the EFA of the CROQ-PTCA Post
items, all items had a greater than 0.4 loading factor. The
CROQ satisfaction was separated into two factors. Three
items about satisfaction were identified as one factor,
while three items about expectation were grouped into an-
other factor. The CROQ adverse effects were separated
into three factors of bruising, pain and numbness, and
tenderness and other problems. In the Japanese study of
42 patients, however, one factor was identified in each do-
main of the CROQ-PTCA Post items [16]. As previously
mentioned, there was no information about the puncture
site of 42 patients in the Japanese study. In our study, par-
ticipants reported almost no puncture site complications.
Therefore, additional studies in patients undergoing PCI
via the femoral artery or who experience more severe ad-
verse effects are needed. In addition, further research
using earlier assessment points than three months will be
required to assess the adverse effects.
The concurrent validity of the CROQ-PTCA (K) was
supported by the pattern of association among the
CROQ, SF-12, and SAQ. The CROQ symptoms were
significantly correlated with the PCS of SF-12 in the
post-test and with the angina frequency scale of the
SAQ. The CROQ physical functioning was significantly
correlated with the PCS of the SF-12 and the physical
limitation scale of the SAQ. The CROQ cognitive func-
tioning and psychosocial functioning were significantly
correlated with the MCS of the SF-12. The CROQ satis-
faction was also significantly correlated with the treat-
ment satisfaction scale of the SAQ. All domains of
the CROQ-PTCA (K), except the cognitive function-
ing domain on the post-PCI test, were significantly
correlated with the quality of life domain of the SAQ.
As a result, the concurrent validity of the CROQ-
PTCA (K) was confirmed.
In this study, the responsiveness of the CROQ-PTCA
(K) was verified. The domain of symptoms was signifi-
cantly improved after PCI. However, psychosocial func-
tioning significantly declined after PCI, while the
domains of physical and cognitive functioning did not
significantly change. This finding can be explained by
the characteristics of our participants. Most participants
in this study were recruited from the outpatient depart-
ment and were therefore not severely ill. We included
only patients who had undergone elective PCI instead of
an urgent procedure. Before the cardiac event, these pa-
tients likely considered themselves to be healthy, so their
physical, cognitive, and psychosocial functioning domains
on the pre-PCI test showed high scores. However, after
the PCI, they might have realized the severity of their dis-
ease and more severely perceived the impact of the disease
on their lives. Given its demonstrated good responsive-
ness, the CROQ-PTCA (K) may be appropriate to detect
important differences in outcomes before and after PCI.
Our study has several limitations that should be men-
tioned. First, the investigation was restricted to patients
receiving elective PCI in hospitals in Korea. Further valid-
ation research with patients undergoing not only elective,
but also urgent PCI is needed. Secondly, the CROQ’s ad-
verse effects showed low reliability. It is possible that the
results would have differed if we had used earlier assess-
ment points than three months to assess the associated
adverse effects. Thirdly, the sample size used to evaluate
the responsiveness of the CROQ was quite small. Further
research will be needed to investigate the responsiveness
of the CROQ for changes in a large sample.
Conclusions
The CROQ was originally developed to assess patients’
specific health-related quality of life (HRQOL) and also to
evaluate treatment effectiveness from the patient’s per-
spective. The Korean version of the CROQ-PTCA demon-
strated good psychometric properties and was responsive
to change. Thus, the CROQ-PTCA (K) is appropriate and
acceptable for detecting meaningful changes that take
place before and after PCI.
Table 6 Responsiveness of the CROQ-PTCA (K)
CROQ scale Mean (SD) Effect size
Pre Mean (median) Post Mean (median) Change Mean (median)
CROQ-PTCA (N = 28)
Symptoms 77.83 (82.1) 94.13 (100.0) 16.31 (17.9)** 1.30
Physical functioning 91.96 (100.0) 94.20 (100.0) 2.23 (0.0) 0.12
Cognitive functioning 95.00 (100.0) 97.62 (100.0) 2.62 (0.0) 0.41
Psychosocial functioning 94.13 (100.0) 85.84 (92.0) -8.29 (-8.0)** -0.50
**p < 0.01
CROQ Coronary Revascularization Outcome Questionnaire, PTCA percutaneous transluminal coronary angioplasty
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